Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
QuintilesIMS
Medtronic
Cerilliant
Healthtrust
Fish and Richardson
Covington
Moodys
Accenture
US Army

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,105,530

« Back to Dashboard

Which drugs does patent 7,105,530 protect, and when does it expire?

Patent 7,105,530 protects VOTRIENT and is included in one NDA.

This patent has thirty-four patent family members in twenty-five countries.
Summary for Patent: 7,105,530
Title:Pyrimidineamines as angiogenesis modulators
Abstract:Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also Includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
Inventor(s): Boloor; Amogh (Lubbock, TX), Cheung; Mui (Durham, NC), Davis; Ronda (Durham, NC), Harris; Philip Anthony (Durham, NC), Hinkle; Kevin (Durham, NC), Mook, Jr.; Robert Anthony (Durham, NC), Stafford; Jeffery Alan (San Diego, CA), Veal; James Marvin (Durham, NC)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:10/451,305
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,105,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,105,530

PCT Information
PCT FiledDecember 19, 2001PCT Application Number:PCT/US01/49367
PCT Publication Date:August 01, 2002PCT Publication Number: WO02/059110

Non-Orange Book US Patents Family Members for Patent 7,105,530

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,262,203 Pyrimidineamines as angiogenesis modulators ➤ Subscribe
7,858,626 Pyrimidineamines as angiogenesis modulators ➤ Subscribe
8,114,885 Chemical compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,105,530

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 430742 ➤ Subscribe
Australia 2002246723 ➤ Subscribe
Brazil 0116452 ➤ Subscribe
Canada 2432000 ➤ Subscribe
China 1307173 ➤ Subscribe
China 1549813 ➤ Subscribe
Cyprus 1117079 ➤ Subscribe
Czech Republic 20031748 ➤ Subscribe
Czech Republic 304059 ➤ Subscribe
Germany 122010000038 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
AstraZeneca
Baxter
Chubb
Teva
Argus Health
Harvard Business School
Queensland Health
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot